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Background. A single dose of perioperative dexamethasone (8–10mg) reportedly decreases postoperative nausea, vomiting, and
pain but has not been widely used in laparoscopic donor nephrectomy (LDN).Methods.We performed a retrospective cohort study
of living donors who underwent LDNbetween 2013 and 2015. Donors who received a lower dose (4–6mg) (𝑛 = 70) or a higher dose
(8–14mg) of dexamethasone (𝑛 = 100) were compared with 111 donors who did not receive dexamethasone (control). Outcomes
and incidence of postoperative nausea, vomiting, and pain within 24 h after LDNwere compared before and after propensity-score
matching. Results. The higher dose of dexamethasone reduced postoperative nausea and vomiting incidences by 28% (𝑃 = 0.010)
compared to control, but the lower dose did not. Total opioid use was 29% lower in donors who received the higher dose than in
control (𝑃 = 0.004). The higher dose was identified as an independent factor for preventing postoperative nausea and vomiting.
Postoperative complication rates and hospital stays did not differ between the groups. After propensity-score matching, the results
were the same as for the unmatched analysis. Conclusion. A single perioperative injection of 8–14mg dexamethasone decreases
antiemetic and narcotic requirements in the first 24 h, with no increase in surgical complications.
1. Introduction
Laparoscopic donor nephrectomy (LDN) has been proven to
be a safe procedure [1–3] and is the gold standard for donor
nephrectomy. LDN has many advantages compared to open
donor nephrectomy, including reduced pain, earlier return to
work, and improved cosmetic results [1]. However, donors
continue to require significant amounts of antiemetics and
opioids postoperatively.
Postoperative nausea and vomiting (PONV) occurs in
50–75% of patients after laparoscopic surgery [4]. One of the
drugs for PONV, dexamethasone, is a long-acting corticos-
teroid known for its antiemetic and anti-inflammatory effects
[5]. Numerous studies led to 4-5mg dexamethasone being
included as a first-line PONV prophylactic agent in several
guidelines [6, 7] for perioperative anesthesia management.
However, in other studies, a higher dose of dexamethasone
(≥8mg or ≥0.1mg/kg) appeared more effective for PONV
than the low dose of 4-5mg [8, 9]. Furthermore, the higher
dose is also effective for pain prophylaxis and the quality of
recovery [4, 9–11], and these effects potentially accelerate the
accomplishment of outpatient surgeries such as laparoscopic
nephrectomy [12]. However, there were no studies regarding
the efficacy of dexamethasone for PONV and pain after LDN.
Opioids play a central role in multimodal analgesia after
LDN; however, side effects such as PONV, sedation, and
reduced gastrointestinal motility [13] affect donor comfort
and raise potentially serious safety concerns in this healthy
population. These side effects have led to the use of the
ketorolac in many centers, despite the low but finite risk of
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Figure 1: Flow chart of study design. PONV: postoperative nausea and vomiting.
serious complications. Achieving donor comfort and safety
while reducing opioids requires an alternative to ketorolac
that would be effective and result in fewer adverse events.
In this retrospective analysis, we examined whether diffe-
rent doses of preoperative dexamethasone would be effective
in reducing PONV and opioid consumption without increas-
ing postoperative complications after LDN.
2. Materials and Methods
2.1. Patient Population. We retrospectively evaluated the
records of 323 consecutive donors who underwent LDN from
February 5, 2013, to October 5, 2015, at the University of
California, San Francisco. Of these, 42 donors were excluded
from the analysis for the following reasons: one had a
history of ulcerative colitis, one had two operations because
the recipient had intraoperative problems during the first
operation (when the first LDNwas taking place), one received
hydrocortisone instead of dexamethasone, and 39 had a prior
history of PONV (confirmed by anesthesiologists by preop-
erative assessment; nine control, 12 low dose, and 18 high
dose, 𝑃 = 0.14), which is a well-established risk factor for
PONV [14] and therefore should be excluded from outcome
analysis [15]. Thus, we compared 70 donors who received
a single intraoperative lowdose (4–6mg) and 100 donorswho
received a single intraoperative high dose (8–14mg) of dex-
amethasone to 111 controls who received no dexamethasone
(Figure 1).
2.2. Data Collection and PerioperativeManagement of Donors.
Demographic data were collected from patients’ electronic
medical records. All donors ceased using tobacco at least
six weeks before LDN. Bowel preparation was done using
bisacodyl oral tablet 5mg daily for three days prior to surgery.
Dexamethasone was administered at the beginning of LDN
according to a request by the anesthesiologist and/or surgeon.
All donors received standard general anesthesia without
epidural analgesia. All nephrectomies were done using the
intraperitoneal pure LDN approach as previously published
[3]. Incisions were as follows: four 5–12mmworking ports in
the right or left mid abdomen and a Pfannenstiel incision (5–
8 cm) made at the end of the LDN for the kidney extraction.
Local anesthesia (bupivacaine, 0.25%, up to 1 cc/kg) was
injected into all incisions at the end of the LDN, and patient-
controlled analgesia was used for the first 24 h after LDN.
Postoperative time was defined as the 24 h period after the
anesthesiologist was no longer in personal attendance.
PONV is difficult to quantitate, particularly in a retrosp-
ective approach. We therefore used administration of anti-
emetics as an objective, surrogate marker for PONV. Notably,
previous prospective studies utilizing subjective PONV scales
have demonstrated that administration of antiemetics is
highly correlated with nausea and vomiting [4, 10]. Ondan-
setron was the first choice of antiemetic drug for PONV
episodes. We recorded the number of antiemetic injections
during the first 24 h after LDN. Intravenous opiate analgesics
included fentanyl andhydromorphone andwere given during
the first 24 h. Donors generally had conversion to oral anal-
gesics between 6 h and 24 h after LDN. Total opiate consump-
tion was converted into an oral morphine equianalgesic dose
[16] and pooled for each of the three groups. Some patients
received ketorolac and/or acetaminophen. Thus, the doses of
all three analgesics (opioid, ketorolac, and acetaminophen)
during the first 24 h after LDN were recorded. The usage of
ketorolac and acetaminophen and their effects on narcotic
consumption were also analyzed.
This study was approved by the Institutional Review
Board of the University of California, San Francisco (study
approval number 15-18306). This was a retrospective study
of the drugs used for known clinical indications; therefore
consent was not obtained.
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2.3. Statistical Analysis. Values are expressed as mean ± stan-
dard deviation unless otherwise specified. The chi-squared
test and Fisher’s exact test were used to analyze categorical
data, and Student’s 𝑡-test, the Mann-Whitney 𝑈 test, and the
Kruskal-Wallis test were used to analyze continuous data.
Bonferroni correction was used for post hoc analysis. Two-
tailed𝑃 values < 0.05 were considered statistically significant.
Univariate and multivariate logistic regression analyses
using pre- and postoperative variables were used to investi-
gatewhether dexamethasone administrationwas an indepen-
dent variable in PONV. Specific variables associated with 𝑃
values < 0.10 by univariate analysis were entered into multi-
variate analysis. The adequacy of the multivariate model was
evaluated using the Hosmer and Lemeshow test.
To further validate the results of this retrospective study,
propensity-score matching [17] was done on preoperative
variables (age, sex, and body mass index (BMI)) between
the control group and the high-dose dexamethasone group.
Matching was done using the 1 : 1 method between ±0.01
differences.
All data were analyzed using SPSS version 23 (SPSS,
Chicago, Illinois, USA). The authors have followed the sug-
gestions of the Strengthening the Reporting of Observational
Studies in Epidemiology (STROBE) statement guidelines for
reporting observational studies [18].
3. Results
3.1. Donor Baseline Variables and Operative Outcomes.
Donor baseline variables and operative outcomes are shown
in Table 1. As expected, the groups were very similar, except
the low dose dexamethasone group that had more women
than the control or high-dose dexamethasone group.Thiswas
in general due to a propensity of some anesthesiologists to
give low dose dexamethasone intraoperatively to womenwho
are at increased risk of PONV [14]. Postoperative hospital
stays and complications did not differ among the groups.
There were no complications in the high-dose group, three in
the low dose group (4.3%; 2 urinary retention, 1 headache),
and three in the control group (2.7%; 1 high-grade fever with
diarrhea, 1 surgical site hematoma, and 1 superficial surgical
site infection requiring bed-side drainage and antibiotics).
No complications were severe; all were below grade II of the
Clavien-Dindo classification [19].
3.2. Dexamethasone Use and PONV. High-dose dexametha-
sone significantly reduced the incidence of PONV by 28%
more than control but the low dose did not (Figure 2). Over
50% of PONV episodes, measured by the number of times
antiemetics were injected, appeared to occur within 6 h after
LDN.Only high-dose dexamethasone reduced the number of
PONV episodes (𝑃 = 0.039, post hoc analysis control versus
high dose 𝑃 = 0.044).
3.3. Univariate andMultivariate Analyses of Factors Associated
with PONV. Female sex, low BMI, longer operative time, a
single injection of high-dose dexamethasone, and the amount
of total opioid were each associated with PONVon univariate
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Figure 2: The incidence of postoperative nausea and vomiting.
∗Chi-squared test. ∗∗Statistically significant by post hoc analysis.
PONV: postoperative nausea and vomiting.
analysis (Table 2). Female sex, low BMI, and a single injection
of high-dose dexamethasone were independent factors asso-
ciated with PONV on multivariate analysis, while low dose
dexamethasone was not (Table 2).
3.4. Postoperative Pain and Intravenous Opioid Doses within
24 h. Total postoperative opioid, ketorolac, and acetamino-
phen consumption with ≤24 h are shown in Figure 3. Over
90% of intravenous opioids were injected ≤6 h after LDN.
A single injection of high-dose dexamethasone significantly
reduced total opioid consumption ≤24 h [35.2 ± 29.8mg
(control) versus 27.8 ± 19.6 (low dose) versus 25.1 ± 28.0mg
(high dose); 𝑃 = 0.011, post hoc analysis control versus high
dose 𝑃 = 0.008, Figure 3(a)].
The total dose of ketorolac and acetaminophen did not
differ between the groups (Figures 3(b) and 3(c)). Among
patients who received ketorolac and/or acetaminophen, post-
operative opioid use increased slightly [26.9 ± 27.5mg (with-
out ketorolac) versus 31.9 ± 27.6mg (with ketorolac), 𝑃 =
0.079, Figure 3(d); 24.7 ± 26.7mg (without acetaminophen)
versus 31.9 ± 27.8mg (with acetaminophen), 𝑃 = 0.002,
Figure 3(e)].
3.5. Propensity-Score Matching Analysis between Control and
High-Dose Dexamethasone. After propensity-score match-
ing for age, sex, and BMI between the control and the higher-
dexamethasone groups, 81 matched pairs were obtained
(Table 3). The results were the same as for the unmatched
analysis in terms of PONV incidence ≤24 h [69.1% (control)
versus 43.2% (high dose), 𝑃 = 0.001] and total opioid con-
sumption≤24 h [39.6±31.4mg (control) versus 25.8±29.2mg
(high dose), 𝑃 = 0.008]. The total dose of ketorolac and
acetaminophen did not differ between the two groups.
4 Journal of Transplantation
Table 1: Donor baseline variables and surgical outcomes.
Control
(𝑛 = 111)
Low dose
dexamethasone
(𝑛 = 70)
High-dose
dexamethasone
(𝑛 = 100)
𝑃 values 𝑃 values
Control
versus
low dose
Control
versus
high dose
Age (years) 43.6 ± 13.4 41.7 ± 13.0 40.5 ± 12.5 0.34 0.09
Sex <0.001 0.56
Male 51 (45.9) 13 (18.6) 42 (42.0)
Female 60 (54.1) 57 (81.4) 58 (58.0)
BMI (kg/m2) 26.5 ± 3.4 25.8 ± 4.1 26.7 ± 3.7 0.31 0.65
ASA 0.18 0.21
1 77 (69.4) 55 (78.6) 77 (77.0)
2 34 (30.6) 15 (21.4) 23 (23.0)
Intraoperative
ondansetron use 103 (92.8) 64 (91.4) 93 (93.0) 0.74 0.95
Operative time (min) 147.8 ± 25.0 148.1 ± 22.7 155.4 ± 24.1 0.93 0.009
Side of nephrectomy 0.013 0.85
Left 91 (81.1) 46 (65.7) 82 (82.0)
Right 20 (18.9) 24 (34.3) 18 (18.0)
Postoperative hospital
stay (days) 2.68 ± 0.62 2.63 ± 0.59 2.66 ± 0.62 0.69 0.86
Complications (%) 3 (2.7) 3 (4.3) 0 (0) 0.68 0.25
Data are expressed as mean ± SD or 𝑛 (%).
ASA: American Society of Anesthesiologists; BMI: body mass index.
Table 2: Univariate and multivariate analyses of factors associated with postoperative nausea and vomiting.
Univariate logistic
regression analysis
Multivariate logistic
regression analysis†
OR 95% CI 𝑃 value OR 95% CI 𝑃 value
Age (per decade) 0.95 0.80–1.14 0.61
Sex (ref. male) 2.81 1.71–4.62 <0.001 2.78 1.60–4.83 <0.001
BMI (per 1 kg/m2) 0.91 0.85–0.98 0.007 0.91 0.85–0.98 0.012
Side of kidney (ref. left) 0.96 0.54–1.68 0.88
ASA (ref. 1) 0.81 0.47–1.39 0.44
Operative time (per 60min) 0.65 0.41–1.03 0.068 1.03 0.61–1.73 0.91
Dexamethasone (ref. control) 0.011 0.041
Low dose 1.08 0.58–2.02 0.81 0.81 0.41–1.60 0.55
High dose 0.48 0.28–0.83 0.009 0.47 0.26–0.86 0.014
Intraoperative ondansetron use 0.53 0.20–1.41 0.20
Ketorolac use (ref. no use) 1.01 0.63–1.63 0.96
Acetaminophen use (ref. no use) 1.43 0.85–2.40 0.17
Total opioid (per 1mg) 1.01 1.00–1.02 0.035 1.01 1.00–1.02 0.058
†Hosmer and Lemeshow Test: 𝑃 value 0.30
ASA: American Society of Anesthesiologists; BMI: body mass index; CI: confidential interval; OR: odds ratio.
4. Discussion
Laparoscopic donor nephrectomy is now a widely accepted
procedure and appears to be as safe as open donor nephrec-
tomy. However, improving donor comfort postoperatively
and preventing narcotic-related complications remains a
primary, important goal. Our study is the first to show that a
single higher (8–14mg) dose of dexamethasone decreases the
use of antiemetics and narcotics after LDN in a statistically
and clinically significantmanner. Specifically, the higher dose
of dexamethasone reduced PONV incidence by 28% and
total opioid use by 29% compared to control, and those
efficacies were further confirmed bymultivariate analysis and
propensity-score matching.
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Figure 3: Box-and-whisker plot graphs showing total postoperative dose (≤24 h) of opioids (a), ketorolac (b), and acetaminophen (c) and
subgroup analyses of opioid consumption with or without ketorolac ≤24 h (d) and with or without acetaminophen ≤24 h (e). Error bars
indicate the highest and lowest occurring value within a 1.5 interquartile range. ∗Post hoc analysis control versus high dose 𝑃 = 0.008
(adjusted).
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Table 3: Donor baseline variables and surgical outcomes in propensity-score matched cohort.
Control
(𝑛 = 81)
High-dose
dexamethasone
(𝑛 = 81)
𝑃 value
Age (years) 41.6 ± 13.2 41.1 ± 11.9 0.84
Sex 0.87
Male 32 (39.5) 33 (40.7)
Female 49 (60.5) 48 (59.3)
BMI (kg/m2) 26.6 ± 3.3 26.8 ± 3.8 0.70
ASA 0.49
1 56 (69.1) 60 (74.1)
2 25 (30.9) 21 (25.9)
Intraoperative
ondansetron use 75 (92.6) 74 (91.4) 0.77
Operative time (min) 140.1 ± 19.5 154.3 ± 22.6 <0.001
Side of nephrectomy 1.00
Left 65 (80.2) 65 (80.2)
Right 16 (19.8) 16 (19.8)
Postoperative hospital
stay (days) 2.73 ± 0.63 2.62 ± 0.62 0.29
Complications (%) 3 (3.7) 0 (0) 0.25
Data are expressed as mean ± SD or 𝑛 (%).
ASA: American Society of Anesthesiologists; BMI: body mass index.
However, general concerns about wound healing or infec-
tion in donors, a healthy patient population, may have pre-
vented dexamethasone from being widely adopted, although
ample evidence indicates that even higher doses of steroids do
not increase wound complications in other types of surgeries
[20]. Our analyses also clearly showed that higher dose dexa-
methasone reduces antiemetic and narcotic consumption
without increasing the incidence of short-term complica-
tions, results that corroborate those of other studies [4, 9–11].
The magnitude of opioid-sparing effect of high-dose
dexamethasone in our study (29%) is in line with previously
published studies [9, 11] (15–50%), and it is in general higher
than for ketorolac [21, 22] (6–22%) or acetaminophen [23]
(16%). Furthermore, the evidence that ketorolac reduces opi-
oid usage after LDN is still lacking. Ketorolac is a nonsteroidal
anti-inflammatory drug [24] that is widely used in many
transplant centers during LDN [25]. A retrospective study of
open donor nephrectomies reported a 58% opioid reduction
in patients who received ketorolac [26]. Although it was one
of the landmark studies regarding the opioid-sparing effect of
ketorolac in the field of donor nephrectomy, that study had
serious confounders such as the use of a historical control
despite the introduction of a new fast-track pathway for
rapid discharge (intravenous hydration, encouraging early
ambulation, and diet progression) in addition to ketorolac.
In fact, several studies [25], including one randomized trial in
patients undergoing LDN [27], showed no benefit of ketoro-
lac on opioid consumption. Consistent with the results of
those studies, our patients who received ketorolac did not
have reductions in antiemetic or narcotic requirements.Thus,
the routine use of ketorolac appears to be unsupported for
LDN [24, 28, 29]. As with ketorolac, we did not find a signi-
ficant impact of acetaminophen on reducing opioid con-
sumption. Acetaminophen has no nephrotoxicity and is less
harmful than ketorolac but may lead to having liver failure
even with a therapeutic dose [30]. Further studies are needed
to confirm the opioid-sparing effect of these medications in
the LDN population.
We recognize that amajor limitation of our study is that it
is a retrospective analysis of a single center. However, several
factors support the conclusions of our study. First, the donor
nephrectomy patients are otherwise healthy and represent a
relatively homogeneous group of patients (in terms of base-
line characteristics including unknown variables) compared
to those undergoing other types of major surgery, and also
LDN was performed in a standardized manner. Notably, the
magnitude of decrease in PONV was similar when control-
ling for surgeon, although the smaller numbers preclude
robust statistical differences (data not shown).The lower dose
dexamethasone hadmore womenwho are at increased risk of
PONV [14].However, we attempted tomitigate this bias using
multivariate logistic regression analysis showing that, even
after the adjustment, the lower dose still had no impact on
preventing PONV in this population. Furthermore, the day to
day postoperative care was similar for all patients regardless
of surgeon or dexamethasone administration, as the inpatient
team follows a standard postoperative routine for donors.
Second, when we performed propensity-score matching to
help mitigate the biases introduced by retrospective studies,
our results were essentially the same. Third, the magnitude
of decrease in PONV and narcotic usage was substantial and
well supported bymultiple trials in other types of surgeries, as
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well as meta-analyses [4, 9–11]. Althoughwe excluded donors
with a prior history of PONV from the analysis, the efficacy
of high-dose dexamethasone compared to control followed
the same pattern if we included those for analyses (data not
shown). Thus, while our study design had limitations, we
believe our conclusions have a high likelihood of validity.
In conclusion, our study shows that a single perioperative
injection of 8–14mg dexamethasone decreased antiemetic
and narcotic requirements in the first 24 h after LDN, with
no increase in short-term complications. This translates into
improved donor comfort and potentially improved safety
through fewer complications associated with narcotic use.
Moreover, dexamethasone is widely available and inexpen-
sive. Thus we believe that it is justified for use in virtually all
laparoscopic donors, as is now the standard at our institution.
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